Cargando…
Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies
COVID-19 is a clinical syndrome ranging from mild symptoms to severe pneumonia that often leads to respiratory failure, need for mechanical ventilation, and death. Most of the lung damage is driven by a surge in inflammatory cytokines [interleukin-6, interferon-γ, and granulocyte-monocyte stimulatin...
Autores principales: | Bonaventura, Aldo, Vecchié, Alessandra, Wang, Tisha S., Lee, Elinor, Cremer, Paul C., Carey, Brenna, Rajendram, Prabalini, Hudock, Kristin M., Korbee, Leslie, Van Tassell, Benjamin W., Dagna, Lorenzo, Abbate, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348297/ https://www.ncbi.nlm.nih.gov/pubmed/32719685 http://dx.doi.org/10.3389/fimmu.2020.01625 |
Ejemplares similares
-
Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial
por: Cremer, Paul C, et al.
Publicado: (2021) -
The Role of GM-CSF Autoantibodies in Infection and Autoimmune Pulmonary Alveolar Proteinosis: A Concise Review
por: Ataya, Ali, et al.
Publicado: (2021) -
Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders
por: Lazarus, Hillard M., et al.
Publicado: (2023) -
Opportunistic Infection Associated With Elevated GM-CSF Autoantibodies: A Case Series and Review of the Literature
por: Lee, Elinor, et al.
Publicado: (2022) -
Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation
por: Bonaventura, Aldo, et al.
Publicado: (2022)